Transfar Capital
Overview
Transfar Capital is the investment arm of Transfar Group, a Chinese conglomerate with business in chemicals, logistics, agriculture, and technology.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Fujian Deer Technology Corp. | Aug 2021 | Series A | Co-investor |
| Wuhan Tacro Technology Co., Ltd. | Jul 2021 | Series A Extension | Co-investor |
| Santo Therapeutics | Dec 2023 | Angel | Lead |
| Arnatar Therapeutics | Dec 2024 | Series A | Co-investor |
| SineuGene Therapeutics | Aug 2024 | VC Round | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Transfar Capital based?
Transfar Capital is headquartered in Hangzhou, China.
When was Transfar Capital founded?
Transfar Capital was founded in 1986.
How many portfolio companies does Transfar Capital have?
Transfar Capital has 5 portfolio companies in Caplight's dataset.
What are some companies in Transfar Capital's portfolio?
Portfolio companies visible on Caplight include Fujian Deer Technology Corp., Wuhan Tacro Technology Co., Ltd., Santo Therapeutics, Arnatar Therapeutics, SineuGene Therapeutics.
What was Transfar Capital's most recent investment shown here?
Transfar Capital's most recent investment in this portfolio sample was in Arnatar Therapeutics in 2024.
What sectors does Transfar Capital focus on?
Transfar Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Healthcare & Life Sciences, Frontier & Industrial Tech, Energy & Sustainability.
What company stages does Transfar Capital focus on?
Transfar Capital typically invests at the Early stage.
What is Transfar Capital's AUM?
Transfar Capital's assets under management are estimated at over $1.4B.